| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 31 Mar 2025 | 31 Mar 2025 |
| Outcome of the Board Meeting held on March 31, 2025. | ||
| Board Meeting | 11 Feb 2025 | 27 Jan 2025 |
| LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2025 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine-months ended December 31 2024 and other business matters. Outcome of Board Meeting - Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (As Per BSE Announcement Dated on 12.02.2025) | ||
| Board Meeting | 7 Nov 2024 | 22 Oct 2024 |
| Quarterly Results LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2024 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2024. Read less.. (As Per BSE Announcement Dated on 22.10.2024) Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2024. (As Per BSE Announcement Dated on: 07/11/2024) | ||
| Board Meeting | 6 Aug 2024 | 23 Jul 2024 |
| LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2024 inter alia to consider and approve the unaudited financial results of the Company for the quarter ended June 30 2024 and other business matters. | ||
| Board Meeting | 6 May 2024 | 22 Apr 2024 |
| LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/05/2024 ,inter alia, to consider and approve audited financial results of the Company for the quarter and year-ended March 31, 2024 and recommend dividend, if any. Approval Of The Audited Financial Statements For The Quarter And Year Ended March 31, 2024 And Recommend Final Dividend @ 400% i.e. Rs. 8/- Per Equity Share Of The Face Value of Rs. 2/- Each For The Year Ended March 31, 2024. Appointment of Mr. Jeffrey Kindler and Mr. Alfonso Zulueta as Independent Directors of the Company effective May 6, 2024. (As Per BSE Announcement Dated on: 06/05/2024) | ||
The drug will be manufactured at Lupin's facility in Nagpur, India, and the company has announced plans for a near-term launch in the U.S. market.
The acquisition enhances Lupin’s portfolio of branded medicines and is aimed at furthering the company’s commitment to providing affordable and sustainable healthcare solutions.
Lupin said the tablets would be made at its Goa facility, which would bolster its global manufacturing capabilities and continued dedication to delivering affordable medications.
Here are some of the stocks that may see significant price movement today: IREDA, Gensol Engineering, Tata Power, etc.
The inspection covered the period from January 27 until January 31, 2025, and was used to assess cGMP and other regulatory requirements at the facility
Here are some of the stocks that may see significant price movement today: Bharti Airtel, Vedanta, Rail Vikas Nigam (RVNL), etc.
Ipratropium Bromide Nasal Solution (0.03%) is indicated for the symptomatic relief of rhinorrhea (runny nose) associated with allergic and nonallergic perennial rhinitis.
Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide tablets are therapeutic equivalents of Symtuza Tablets 800 mg/150 mg/200 mg/10 mg brand of Janssen Products, LP.
Here are some of the stocks that may see significant price movement today: Tata Motors, BHEL, Hindalco, Lupin, etc.
Lupin was already selling Huminsulin under the license agreement entered with Lilly India.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
